Healthcare
SanBio Company Limited(SNBIF)
Live Price
Offline$16.45
+0.00% today
1Y Change
+151.15%
Window
Jun 23, 2025 โ Jun 18, 2026
- Market Cap
- $153.74B
- Revenue Growth
- 0.0%
- EPS Growth
- -25.8%
- Dividend Yield
- 0.0%
Coverage: 254 bars ยท Jun 23, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SanBio Company Limited (SNBIF) is a Healthcare stock with a market cap of $153.74B and listed on OTC. The stock last traded around $16.45 and up 151.1% across the available one-year price window (Jun 23, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -25.8%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -25.8%, free cash flow -6.4% with operating margin 0.0% and ROIC -22.3%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SNBIF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Jun 17, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -25.8%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Jun 17, 2026 | โ | +0.0% | โ | โ |
2026 Jun 12, 2026 | โ | +0.0% | โ | โ |
2026 Mar 17, 2026 | +28.5% | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SNBIF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SNBIF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SNBIF and SPY.
Company Overview
SanBio Company Limited
Other OTC
SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
- Leadership
- Keita Mori
- IPO Date
- Oct 12, 2015
- Employees
- 29
- Street Address
- St. Luke Tower
- Mailing
- Tokyo, 104-0044
- Region
- Tokyo, JP
- Reporting Currency
- USD
- Investor Line
- 81 3 6264 3481
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 11.0
Growth
- Revenue
- 0.0%
- EPS
- -25.8%
- Free Cash Flow
- -6.4%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -88.9%
- ROIC
- -22.3%
Balance Sheet
- Debt/Equity
- 0.09
- Current Ratio
- 28.99
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.